Breaking the cycle: enhancing medication adherence in pcos and pcod management
DOI:
https://doi.org/10.22376/ijtos.v3i3.78Keywords:
Polycystic ovarian syndrome, polycystic ovarian disease, androgen excess, menstrual irregularity, infertility, abnormal weight gainAbstract
Polycystic ovary syndrome (PCOS) and polycystic ovarian disease (PCOD) is one of the prevalent endocrine disorders affecting women of reproductive age, with an estimated prevalence of 5-10%. PCOD is one of the most prevalent metabolic and reproductive disease. This is a medical condition where women’s ovaries generate a significant number of immature or partially mature eggs, which eventually develop in to a ovarian cyst. As a result, the ovarian grows large and secretes more androgens, irregular menstruation periods, abnormal weight gain, hair loss and infertility.
References
Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol. 1935;29(2):181–91.
Singh S, Pal N, Shubham S, Sarma DK, Verma V, Marotta F, et al. Polycystic ovary syndrome: etiology, current management, and future therapeutics. J Clin Med. 2023;12(14):1454.
Ganie MA, et al. Epidemiology, pathogenesis, genetics & management of polycystic ovary syndrome in India. Indian J Med Res. 2019;10:333–44.
Shahebrahimi K, et al. Comparison clinical and metabolic effects of metformin and pioglitazone in polycystic ovary syndrome. Indian J Endocrinol Metab. 2016;20(6):805–9.
Lim S, Wright B, Savaglio M, Goodwin D, Pirotta S, Moran L. An analysis on the implementation of the evidence-based PCOS lifestyle guideline: recommendations from women with PCOS. Semin Reprod Med. 2021;39(3–4):153–60.
Sadeghi HM, Adeli I, Calina D, Docea AO, Mousavi T, Daniali M, Nikfar S, Tsatsakis A, Abdollahi M, editors: Khan RN, Amer S. Polycystic ovary syndrome: a comprehensive review of pathogenesis, management, drug repurposing. (Book chapter or review). PMCID: PMC8775814; PMID: 35054768.
Cambridge Textbook of Obstetrics and Gynaecology. (Edition/year not specified.)
Bopaliya J, Raole V. Ayurveda management of polycystic ovarian disease (PCOD): a case report. Int J Biol Pharmacy Allied Sci. 2025;14(6):3342–51. DOI:10.31032/IJBPAS/2025/14.6.9095.
Thomas JE, et al. Investigating the impact of lifestyle factors on PCOD: a comprehensive analysis. (Details [journal/year/volume/pages] not specified.)
Stener Victorin E, Teede H, Piltonen TT, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2024;10:27. Published 18 April 2024.
Teede HJ, et al. Recommendations from the 2023 International Evidence based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Fertil Steril. 2023. DOI:10.1016/j.fertnstert.2023.07.025.
Lanzone A, Fulghesu AM, Pappalardo S, Proto C, Le Donne M, Andreani CL, Muscatello R, Caruso A, Mancuso S. Growth hormone and somatomedin C secretion in patients with polycystic ovarian disease: their relationships with hyperinsulinism and hyperandrogenism. (Details [journal/year/volume/pages] not specified.)
Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta analysis. Hum Reprod. 2016;31(12):2841–55.
UNICEF India. PCOD vs PCOS Explainer. (Web resource—include URL and Access date.)
Khatuja R, et al. Prevalence and phenotypic profile of polycystic ovary syndrome in Indian women: a systematic review and meta-analysis. Int J Gynaecol Obstet. 2023. (Volume/pages not specified.)
Norman RJ, Teede HJ. A new evidence based guideline for assessment and management of polycystic ovary syndrome. Med J Aust. 2018 Sep 1;209: (page number not specified).
Balen AH, Conway GS, Kaltsas G, Techatraisak K, Manning PJ, West C, Jacobs HS. Andrology: polycystic ovary syndrome: the spectrum of the disorder in 1,741 patients. (Details [journal/year/volume/pages] not specified.)
Declercq JA, Van de Calseyde JF. Polycystic ovarian disease: diagnosis, frequency and symptoms in a general gynaecological practice. BJOG. 1977;84(5):380–85.
Heineman MJ, Thomas CMG, Doesburg WH, Rolland R. Hormonal characteristics of women with clinical features of the polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 1984;17(4):263–71.
Puttabyatappa M, Padmanabhan V. Ovarian and extra ovarian mediators in the development of polycystic ovary syndrome. Mol Endocrinol. 2018 Oct;61(4):R161–R184.
Combs JC, Hill MJ, Decherney AH. Polycystic ovarian syndrome genetics and epigenetics. Clin Obstet Gynecol. 2021 Mar;64(1):20–25.
Polycystic Ovary Syndrome (PCOS): State of the Art. [Textbook—editor/year not specified.]
Sanchez Garrido MA, Tena Sempere M. Global prevalence and risk factors of PCOS: a systematic review and meta-analysis. 2024. (Journal/volume/pages not specified.)
WHO. Women’s health & reproductive disorders. (Web resource—include URL and Access date.)
Patel S. Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy. J Steroid Biochem Mol Biol. 2018 Sep; (volume/pages not specified.)
Thompson S. Demystifying PCOS: What You Need to Know. (Source/year not specified.)
Gu Y, et al. Life modifications and PCOS: old story but new tales. Front Endocrinol (Lausanne). 2022; (volume/pages not specified.)
Macut D, et al. Insulin and the polycystic ovary syndrome. Diabetes Res Clin Pract. 2017 Aug; (volume/pages not specified.)
Meng Y, Zhao T, Zhang R, Zhu X, Ma C, Shi Q. Global burden of polycystic ovary syndrome among women of childbearing age, 1990–2021: a systematic analysis using the global burden of disease study 2021. Front Public Health. 2025;13:1514250. DOI:10.3389/fpubh.2025.1514250.
Lin T, Xie B, Yang J, Xu B, et al. Changes in the global burden of polycystic ovary syndrome from 1990 to 2021. Reprod Health. 2025;22:86. DOI:10.1186/s12978-025-02016-y.
Published
How to Cite
Issue
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
